Science & Products

Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases

Release Time:

2025-09-28

Source:

Bioheng

Reprint to:

Linkedin

null

Presentation

Contact Us

Consult Now